Both IS improve the pharmacokinetic profile of IFX
Both IS improve the pharmacokinetic profile of IFX. The efficacy data of IFX treatment in rheumatoid arthritis (RA) and Crohn’s disease clearly show the synergistic effect of concomitant IS treatment on IFX response.11,12,13,14,15,16 There are several hypotheses on why concomitant IS treatment may lead to better effectiveness of IFX. therapy experienced lower IFX levels (median…
Read More “Both IS improve the pharmacokinetic profile of IFX” »